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Acute promyelocytic leukemia (APL) is characterized by the
translocation t(15;17)(q22;q21), resulting in the promyelocytic
leukemia (PML)-retinoic acid receptor alpha (RARA) fusion
protein1 in 95% cases whereas variant translocations involving
PLZF (11q23), NPM (5q35), NUMA (11q13) and STAT5b
(17q23) account for the rest.2 Leukemias with PML-RARA
translocations respond well to all-trans retinoic acid (ATRA) or
arsenic trioxide (ATO) therapy3 whereas those with PLZF-RARA
fusions respond poorly. Although primary resistance to ATRA is
rare, secondary or acquired resistance is frequently observed in
patients treated with ATRA alone or in combination with other
chemotherapy regimens. However, molecular abnormalities
mediating resistance to ATRA therapy are underexplored. Here,
we report two cases of APL with RARA-PML deletions on der(17)
or der(15), which displayed clinical evidence of primary and
secondary resistance to therapy, respectively.
Patient 1 is a 63-year-old Caucasian male presented with
pancytopenia and gastrointestinal bleeding. Morphologic eva-
luation of the blood smear showed blasts with Auer rods and
cytologic features of hypergranular or ‘typical’ APL. Flow
cytometry demonstrated 41% blasts with the phenotype:
CD34, CD117þ , CD33þ , CD13þ , human leukocyte antigen
(HLA)-DR, CD56þ , myeloperoxidase (MPO)þ and CD64þ .
Karyotype analysis revealed 46,XY,t(15;17)(q22;q21)[19]
(Figure 1a). Fluorescence in situ hybridization (FISH) analysis
using PML/RARA dual fusion probes detected an unusual signal
pattern in 74.6% cells (one fused, one green, one red signal)
instead of the expected pattern (two fused; one on each
derivative chromosome, one red, and one green on normal 15
and 17, respectively). Analysis of metaphases allowed mapping
of the deleted fusion signal to der(17)t(15;17) (Figure 1d) and
showed a residual PML signal on der(17) (Figure 1d), suggesting
that the deletion encompassed a major part of the 30 end of
PML and the entire 50 end of RARA on der(17)t(15;17). On















Figure 1 Identification of deletions on der(17) in APL Patient 1. (a) Partial karyotype showing t(15;17) (arrows). (b–c) Pseudo-colored SKY
karyotype (b) and partial metaphase of spectral image (c) showing t(15;17) and ider(17). Arrowhead indicates der(15) and arrows showing ider(17).
(d) Detection of deletion on der(17) (arrow) using PML/RARA dual fusion probe. PML labeled with spectrum red and RARA with spectrum green.
(e) FISH analysis shows the retention of Her-2/neu gene on ider(17) chromosomes (arrows). Green signals indicate centromere 17 and red signals
are Her-2/neu. (f) Schematic presentation of der(17)t(15;17) showing the estimated size of the deletion (not drawn to scale).
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two (36%) copies of ider(17)(q10)t(15;17) were also identified
(Figure 1b–c and e). Spectral karyotype (SKY) analysis, per-
formed to rule out other cryptic abnormalities, confirmed the
t(15;17)(q22;q21) and ider(17)(q10)t(15;17) (Figure 1b and c).
The patient achieved hematologic remission after treatment
with ATRA and idarubicin. However, a bone marrow biopsy 30
days post-therapy showed dysplastic myeloid maturation and
flow cytometry detected 2% blasts. Karyotype analysis showed
46,XY,t(15;17)(q22;q21)[6]/46,XY[14] and FISH with PML/
RARA probes confirmed t(15;17) in 69.7% cells with a single
fusion signal. These findings were consistent with primary
resistance to therapy. After re-induction therapy with addition of
ATO, the patient is currently in complete hematologic and
cytogenetic remission.
Patient 2 is 18-year-old female presented with 2 days of
petechiae and intra-cranial hemorrhage. The initial white
blood cell count was 38 000 106/l and platelet count was
15 000 106/l. Review of the marrow aspirate showed 90%
blasts, many with Auer rods, which had morphologic features of
‘typical’ APL. Flow cytometry detected 80% blasts with the
phenotype: CD34, CD117þ , CD33þ , CD13þ , HLA-DR,
MPOþ and CD64þ . Karyotype analysis showed 46,XX,t(15;17)
(q22;q21)[5]/47,XX,idem,þ 8[15]. FISH analysis using PML/
RARA dual fusion probes detected a typical signal pattern in
97.1% cells (Figure 2a). During induction treatment (ATRA
and daunorubicin 200 mg/m2), the patient developed ATRA
syndrome, and was treated with steroids and dose reduction of
ATRA. She achieved morphologic and cytogenetic remission
after consolidation treatment with two cycles of ATO and
daunorubicin (300 mg/m2). After 23 months of remission, her
leukemia relapsed. The marrow aspirate showed 87% blasts
with a phenotype identical to the primary APL. Karyotype
analysis demonstrated 46,XX,t(15;17)(q22;q21)[17]/46,XX[3].
FISH analysis using PML/RARA probes revealed 96.3% cells
with rearrangement and deletion of PML on der(15) (Figure 2b–
d), which was suggestive of a deletion involving the 50 end of
PML gene on der(15). To determine the size of this deletion, we
performed FISH utilizing probes flanking both sides of the PML
breakpoint. FISH analysis with a 96 kb bacterial artificial
chromosome (BAC) clone spanning intron 4 and all of the 30
end of the PML breakpoint confirmed retention of the 30 end of
the translocated PML on der(17) and a residual signal on der(15),
consistent with the PML breakpoint being distal to exon 5
(Figure 2f). Two BAC clones spanning 376 to 107 kb 50 of the
PML gene, showed no evidence of deletions on der(15)
(Figure 2e). The size of the deletion was estimated to be 100–
150 kb based on loss of the major portion of the 50 end of PML
and retention of signals upstream of the PML gene. These data
suggest that PML deletion on der(15) might be responsible with
secondary resistance to therapy. After re-induction with
der(15)
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Figure 2 Identification of deletion on der(15) in APL Patient 2. (a) Interphase FISH analysis using PML/RARA dual fusion probe shows two
fused signals (arrow heads) in blasts from the primary sample. (b–d) Metaphase FISH analysis of PML/RARA probe showing one fused signal and
deletion of PML on der(15) at relapse (arrow). (b) Both probes, (c) only PML probe (red) hybridization of the same metaphase shown in (b) with
deletion of PML region on der(15) indicated by arrow, and (d) only RARA probe (green) hybridization of the same metaphase shown in (b and c)
with the retention of translocated RARA on der(15) (arrow). (e) Metaphase FISH analysis showing retention of BAC RP11-24D15 on der(15) (arrow)
mapped 107 kb upstream of PML (green) and red signals indicate centromere 15. (f) FISH analysis of a spectrum red labeled BAC clone (RP11-
756N20) spanning intron 4 and the remaining 30 end of PML showing retention of signals on der(17) (red-green signal) and residual signal on
der(15) (red) (arrow). Green signals indicate centromere 17. (g) Schematic representation of probes used, showing estimated size of the 50 end of
PML deletion on der(15) (not drawn to scale).
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ATOþATRA, the patient is in complete remission 1 month post-
mismatched unrelated donor stem cell transplant.
Submicroscopic deletions associated with chromosomal
translocations/inversions have been documented in chronic
myeloid leukemia (CML) and leukemias with t(8;21), inv(16)/
t(16;16), or mixed lineage leukemia translocations.4 Deletions
in CML patients have been associated with refractory disease
and a poor outcome.5 Chromosomal deletions associated with
t(15;17) have not been reported in APL.4 Similar to CML,
submicroscopic deletions in our first case encompassed a large
region (B300 kb) 30 of the PML gene and the entire 50 of the
RARA gene including exons 1 and 2, spanning a region of
B250 kb. The Her-2/neu gene, which maps 580 kb proximal to
RARA, was retained (Figure 1e, f) suggesting that the deletion
breakpoint on der(17) was between 250 and 500 kb centromeric
to RARA. To our knowledge, this is the first described case of
APL that demonstrated chromosomal deletions in association
with a RARA/PML translocation and exhibited primary resis-
tance to ATRA-based therapy. We propose that the genetic
deletions on either side of the translocation on 17q might be
responsible for the primary resistance. The 300 kb deleted
region, distal to PML on der(17q), contains ISLR, STRA6 and
CYP11A1 and loss of one of these genes might account for
resistance to therapy. The 400 kb genomic region proximal to 50
RARA on 17q is a gene-rich region, which contains CDC6,
WIRE, RAPGEFL1, CASC3, NR1D1, THRA, THRAP4, CSF3,
PSMD3, GSDM1, ORMDL3, GSDML and SPBP2. Haploinsuffi-
ciency of some of these genes may function as tumor
suppressors or modifiers. The ider(17) chromosome resulted in
TP53 gene deletion (data not shown), which may further
contribute to growth advantage and treatment resistance. Thus,
as in CML, large deletions accompanying translocations in APL
might impart a proliferative advantage, resistance to cell death,
or lead to differentiation arrest.
Primary resistance of APL with t(15;17) to ATRA induction
therapy is rare but secondary resistance and relapse of disease
after clinical remission has been described. Deletions in the
carboxy terminus of PML exon 6,6 mutations of the normal PML
allele7 and insertions in RARA intron 28 have been shown to
reduce sensitivity to maturation inducing agents and secondary
resistance to therapy. Our second case demonstrated aB100 kb
deletion in the amino terminus of PML, 50 of exon 6 on der(15).
Two genes, STOML1 (12 kb) and LOXL1 (68 kb), that map
immediately upstream are the likely targets of this deletion.
Although the function of STOML1 is unknown, LOXL1 is
implicated in developmental regulation, senescence, tumor
suppression, cell growth control and chemotaxis. Haploinsuffi-
ciency or loss of function of these genes may play a role in
secondary resistance. Further studies are needed to delineate the
frequency of submicroscopic deletions in APL and their
molecular and clinical consequence.
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Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E
and E627E
Leukemia (2006) 20, 2195–2197. doi:10.1038/sj.leu.2404325;
published online 27 July 2006
The V617F point mutation of the JAK2 gene (located in
chromosome 9p24) shows a high frequency in diverse BCR-
ABL-negative chronic myeloproliferative disorders. A thymidi-
ne4guanine substitution at position 1849 leads to a valine to
phenylalanine exchange at amino acid 617, which is localized
in exon 12. The highest frequency of point mutations of the JAK2
gene is found in polycythemia vera (80–95% of all cases), which
is followed by essential thrombocytosis and idiopathic osteo-
myelofibrosis (40–55% of all cases). The mutation is further
known to occur at low frequency in the so-called unclassifiable
MPS (according to the WHO classification), in chronic
myelomonocytic leukemia, in myelodysplastic syndrome and
in acute myeloid leukemia (AML).1–5 The cytoplasmic non-
receptor Janus kinases regulate tyrosine phosphorylation of
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